Our clinical trials unit has participated in the development of the AMBAR study, carried out at the General University Hospital of Catalonia and the ACE Foundation. It aims to reduce cerebral amyloid and improve cognitive performance, through plasmapheresis and the plasmatic replacement of albumin and / or immunoglobulins. This phase II/III trial has shown positive results in patients with moderate-stage Alzheimer’s disease. Dr. Balaguer, principal investigator, has participated at the investigators meeting that took place in Clayton, NC, USA on January 29, 2019.
